Beurs gesloten -
Hong Kong S.E.
10:08:20 26-04-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
16,5
HKD
|
+0,98%
|
|
+11,34%
|
+18,71%
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Marktkapitalisatie
1 |
19.793
|
21.477
|
9.765
|
6.144
|
6.866
|
8.301
|
-
|
-
|
Bedrijfswaarde
1 |
18.101
|
22.196
|
9.765
|
6.144
|
6.866
|
8.301
|
8.301
|
8.301
|
K/w-verhouding
|
-20,7
x
|
-21
x
|
-9,82
x
|
-8,83
x
|
12,6
x
|
13,7
x
|
11,5
x
|
9,94
x
|
Dividendrendement
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Marktkapitalisatie/omzet
|
218
x
|
36,6
x
|
5,8
x
|
1,91
x
|
1,27
x
|
1,41
x
|
1,29
x
|
1,12
x
|
Bedrijfswaarde/omzet
|
218
x
|
36,6
x
|
5,8
x
|
1,91
x
|
1,27
x
|
1,41
x
|
1,29
x
|
1,12
x
|
Bedrijfswaarde/EBITDA
|
-25,7
x
|
-25
x
|
-23,3
x
|
-19,8
x
|
6,72
x
|
7,73
x
|
6,91
x
|
5,92
x
|
Bedrijfswaarde/FCF
|
-14,5
x
|
-17,8
x
|
-9,38
x
|
-
|
12
x
|
-692
x
|
24,5
x
|
9,73
x
|
FCF Yield
|
-6,89%
|
-5,62%
|
-10,7%
|
-
|
8,36%
|
-0,14%
|
4,08%
|
10,3%
|
Price to Book
|
4,53
x
|
6,71
x
|
4,25
x
|
3,75
x
|
-
|
2,94
x
|
2,5
x
|
2,06
x
|
Aantal aandelen (in duizenden)
|
543.495
|
543.495
|
543.495
|
543.495
|
543.495
|
543.495
|
-
|
-
|
Referentieprijs
2 |
36,42
|
39,52
|
17,97
|
11,30
|
12,63
|
15,27
|
15,27
|
15,27
|
Datum van publicatie
|
23/03/20
|
26/03/21
|
16/03/22
|
31/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Omzet
1 |
90,93
|
587,6
|
1.682
|
3.215
|
5.395
|
5.894
|
6.460
|
7.425
|
EBITDA
1 |
-768,7
|
-857,8
|
-420
|
-310,6
|
1.021
|
1.074
|
1.202
|
1.402
|
Bedrijfsresultaat (EBIT)
1 |
-851,2
|
-993,6
|
-620,2
|
-323,8
|
662
|
759,5
|
856,7
|
1.087
|
Operationele Marge
|
-936,09%
|
-169,09%
|
-36,86%
|
-10,07%
|
12,27%
|
12,89%
|
13,26%
|
14,65%
|
Resultaat voor belastingen (EBT)
1 |
-874,8
|
-993,5
|
-956,7
|
-693,9
|
569,6
|
676,5
|
808,9
|
964,5
|
Nettowinst (verlies)
1 |
-875,5
|
-993,5
|
-984,1
|
-695,3
|
546
|
600,5
|
712,5
|
893,7
|
Nettomarge
|
-962,8%
|
-169,09%
|
-58,49%
|
-21,63%
|
10,12%
|
10,19%
|
11,03%
|
12,04%
|
WPA
2 |
-1,760
|
-1,880
|
-1,830
|
-1,280
|
1,000
|
1,117
|
1,329
|
1,536
|
Free Cash Flow
1 |
-1.364
|
-1.207
|
-1.041
|
-
|
574,2
|
-12
|
339
|
853
|
FCF-marge
|
-1.500,51%
|
-205,34%
|
-61,86%
|
-
|
10,64%
|
-0,2%
|
5,25%
|
11,49%
|
Kasstroomconversie (ebitda)
|
-
|
-
|
-
|
-
|
56,23%
|
-
|
28,2%
|
60,85%
|
Kasstroomconversie (nettowinst)
|
-
|
-
|
-
|
-
|
105,17%
|
-
|
47,58%
|
95,45%
|
Dividend per aandeel
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
23/03/20
|
26/03/21
|
16/03/22
|
31/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Nettoschuldpositie
|
-
|
719
|
-
|
-
|
-
|
-
|
-
|
-
|
Nettokaspositie
|
1.692
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Hefboom (schuld/ebitda)
|
-
|
-0,8386
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1.364
|
-1.207
|
-1.041
|
-
|
574
|
-12
|
339
|
853
|
ROE (netto-inkomsten/eigen vermogen)
|
-30,2%
|
-27,6%
|
-35,8%
|
-35,4%
|
28,5%
|
27,2%
|
28,8%
|
28,4%
|
ROA (netto-inkomsten/totale activa)
|
-
|
-16,1%
|
-
|
-
|
-
|
6,9%
|
6,05%
|
6,4%
|
Totale activa
1 |
-
|
6.169
|
-
|
-
|
-
|
8.703
|
11.777
|
13.964
|
Nettoactief per aandeel
2 |
8,050
|
5,890
|
4,230
|
3,010
|
-
|
5,200
|
6,100
|
7,400
|
Cashflow per aandeel
|
-
|
-1,230
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
289
|
557
|
460
|
585
|
474
|
688
|
615
|
601
|
Capex/omzet
|
317,77%
|
94,79%
|
27,37%
|
18,2%
|
8,78%
|
11,67%
|
9,52%
|
8,09%
|
Datum van publicatie
|
23/03/20
|
26/03/21
|
16/03/22
|
31/03/23
|
21/03/24
|
-
|
-
|
-
|
Gemiddeld advies Accumuleren Laatste slotkoers
15,27
CNY Gemiddelde koersdoel
16,39
CNY Spread / Gemiddelde doel +7,30% Consensus |
Vaira. 1 jan.
|
Kapi.
|
---|
| +18,71% | 1,15 mld. | | -4,66% | 86,13 mld. | | +1,32% | 39,82 mld. | | -19,27% | 30,42 mld. | | +57,86% | 25,23 mld. | | -16,09% | 15,35 mld. | | -9,14% | 11,95 mld. | | -17,69% | 11,6 mld. | | -43,00% | 11,51 mld. | | +5,24% | 8,71 mld. |
Biofarmaceutica
|